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Abstract
Evidences from animal models and humans have implied the involvement of alterations 
in the gut microbiota in development of some autoimmune diseases. Dysbiosis observed 
in autoimmune diseases is associated with decreased bacteria function and diversity, 
impaired epithelial barrier function, inflammation, and decreased regulatory T cells in 
the gut mucosa. Studies suggest that probiotics influence systemic immune responses, 
ensure the homeostasis of the healthy microbiota in the intestinal mucosa, and could, 
therefore, be used as adjuvant therapy to treat immune-mediated diseases. The mecha-
nisms proposed to achieve this include mucus secretion; antimicrobial peptide produc-
tion; the maintenance of the function of the gastrointestinal-epithelial barrier, ensuring 
adequate interactions between the gut microbiota and the mucosal immune cells; and, 
finally, helping the activation of host immune system in response to pathobionts. Here, 
we described several reports concerning probiotic applications in several animal models 
of autoimmune diseases and data of the main clinical trials concerning the applicability 
of probiotics in type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and systemic 
lupus erythematosus.
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1. Introduction
Thousands of years ago, Hippocrates, father of medicine, coined the concept that food would 
serve as medicine and postulated, “Let food be thy medicine, and let medicine be thy food.” 
Nowadays, the concept of food as a medicine appeared as functional foods, referring to any 
foods or ingredients with nutritional value and that promote a health benefit to the host [1]. 
Probiotics, prebiotics, and synbiotics are the most popular ingredients used as functional 
foods and dietary supplements [2].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
According to the World Health Organization (2002) and the International Scientific Association 
for Probiotics and Prebiotics (2013), probiotics is defined as “a live organism, which provides a 
benefit to the host when provided in adequate quantities” [2–4]. Most commonly used probiotic 
includes lactic acid-producing bacteria, such as Lactobacillus, Bifidobacterium, and Streptococcus 
species. Non-lactic acid-producing bacteria, such as Bacillus and Propionibacterium, species 
and nonpathogenic yeasts, including Saccharomyces boulfecesardii, non-spore-forming and non-
flagellated rod or coccobacilli, and some helminths, such as Trichuris suis ova, could also been 
used as probiotics [5, 6]. Some of these strains were chosen based on origin, in vitro adherence 
to intestinal cells, and survival during passage through the gastrointestinal tract [5].
2. Intestinal dysbiosis in autoimmune diseases
Evidence from animal models has implied the involvement of intestinal dysbiosis in develop-
ment of some autoimmune diseases [24–26]. Dysbiosis observed in autoimmune diseases is 
associated with decreased bacteria function and diversity, impaired epithelial barrier func-
tion, inflammation, and decreased regulatory T cells (Treg cells) in the gut mucosa [7, 8]. The 
hypotheses proposed to link dysbiosis with autoimmune diseases include molecular mim-
icry, bystander T cell activation, and the amplification of autoimmunity by pro-inflammatory 
cytokines, which is elicited by dysbiotic gut microbiota [9]. In 2016, Lerner and colleagues, 
from Institute Wendelsheim, in Germany, proposed the posttranslational modification of 
luminal proteins, promoted by enzymes from altered microbiota, which modify substrates in 
a different way than performed under homeostatic conditions. The defective posttranslational 
modification of luminal proteins could generate neo-epitopes that may become immunogenic 
and induce systemic autoimmunity and trigger autoimmune diseases [9].
Here, we described several reports concerning probiotic applications in several animal mod-
els of autoimmune diseases and data of the main clinical trials concerning the applicability 
of probiotics in type 1 diabetes (T1D), multiple sclerosis (MS), rheumatoid arthritis (RA), and 
systemic lupus erythematosus.
3. Probiotics in autoimmune diseases
Studies suggest that probiotics influence systemic immune responses, ensure the homeostasis 
of the healthy microbiota in the intestinal mucosa, and could, therefore, be used as adjuvant 
therapy to treat immune-mediated diseases [4]. The mechanisms proposed to achieve this 
include mucus secretion, antimicrobial peptide production, the maintenance of the function 
of the gastrointestinal-epithelial barrier, decreasing oxidative stress, ensuring adequate inter-
actions between the gut microbiota and the mucosal immune cells, and, finally, helping the 
activation of host immune system in response to pathobionts [10].
3.1. Type 1 diabetes
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by autoimmune reactions 
against the insulin-secreting pancreatic β-cells, resulting in exogenous insulin dependence 
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to control blood glucose levels [11]. The etiopathogenesis may involve the interaction of pre-
disposing human leucocyte antigens (HLA) alleles and environmental factors, such as viral 
infections, vitamin deficiencies, and disruption of the gut microbiota [12]. According to the 
International Diabetes Federation, more than 96,000 children and adolescents under 15 years 
will be diagnosed with T1D annually worldwide, and this number is estimated to be more 
than 132,600 when the age range extends to 20 years [13].
The role of the gut microbiota in T1D etiology has been the subject of research over the last 
decade to clarify its role in disease development and determine preventive approaches, such 
as diet manipulation and probiotic administration [12]. Several researches have been carried 
out to verify whether the administration of probiotics may improve the prognosis of diabetes 
through modulation of gut microbiota. Probiotics have been identified as effective adjuvants 
in insulin resistance therapies [14–16]. This health claims apparently stem from the ability of 
probiotics to secrete antimicrobial substances, competing with other pathogens, strengthen-
ing the intestinal barrier, and modulating the immune system [17].
3.1.1. Probiotics in animal models of autoimmune diabetes
The intestinal microbiota might modulate the autoimmune T1D pathogenesis via two mecha-
nisms, recently proposed by Knip and Honkanen [18], from the University of Helsinki, in 
Finland. In the first phase, an impaired tolerance process in infancy leads to a susceptibility 
to develop autoimmune diseases, such as T1D, and may result in appearance of autoreactive 
T cells and autoantibodies. At the second phase, the intestinal dysbiosis predisposes children 
with genetic susceptibility and positive autoantibodies to develop clinical disease [18].
The inflammasome signaling components are innate immune sensors that are highly influ-
enced by the gut environment and play pivotal roles in maintaining intestinal immune 
homeostasis [19]. Previous studies suggested the involvement of the gastrointestinal tract in 
the pathogenesis of islet autoimmunity. Thus, the modulation of gut-associated lymphoid tis-
sue may represent a means to affect the natural history of the disease. Oral administration of 
probiotics can modulate local and systemic immune responses [20].
The earliest study to evaluate the efficacy of probiotics in T1D was published in 2005. The study 
performed by Calcinaro and colleagues, in the University of Perugia, in Italy, investigated 
the effects of oral administration of the probiotic VSL#3 in nonobese diabetic (NOD) mice 
development. VSL#3 was administered to female NOD mice three times a week starting from 
4 weeks of age. Early oral administration of VSL#3 prevented diabetes development in NOD 
mice. Protected mice showed reduced insulitis and a reduced β-cell destruction. Prevention 
was associated with an increased production of interleukin (IL)-10 from Peyer’s patches and 
the spleen and with increased IL-10 expression in the pancreas, where IL-10-positive islet-
infiltrating mononuclear cells were detected. The protective effect of VSL#3 was transferable 
to irradiated mice receiving diabetogenic cells and splenocytes from VSL#3-treated mice. Oral 
VSL#3 administration prevents autoimmune diabetes and induces immunomodulation by 
a reduction in insulitis. These data provide a sound rationale for future clinical trials of the 
primary prevention of T1D by oral VSL#3 administration [21].
Eleven years later, Kim and colleagues evaluated the effects of Bifidobacterium lactis HY8101 
on insulin resistance induced by tumor necrosis factor-alpha (TNF-α) in the skeletal muscle 
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cell from L6 rat. The treatment using HY8101 improved the insulin-stimulated glucose uptake 
and translocation of GLUT4 via the insulin signaling pathways AKT and IRS-1(Tyr) in TNF-
treated L6 cells. HY8101 increased the mRNA levels of GLUT4 and several insulin sensitiv-
ity-related genes in TNF-α-treated L6 cells. HY8101 improved diabetes-induced plasma total 
cholesterol and triglyceride levels and increased the muscle glycogen content. Bifidobacterium 
lactis HY8101 can be used to moderate glucose metabolism, lipid metabolism, and insulin sen-
sitivity in mice and in cells. Bifidobacterium lactis HY8101 might have potential as a probiotic 
candidate for alleviating metabolic syndromes such as diabetes [22].
Another work, performed in Yale University, by Peng and colleagues, in 2014, demonstrated 
that the protection from T1D development observed in MyD88-deficient NOD mice (MyD88−/−
NOD) could be transferred to wild-type NOD mice [23, 24]. The gut bacteria isolated from 
MyD88−/−NOD mice, administered over a 3-week period, altered the family composition of 
the gut microbiome, mainly increasing the Lachnospiraceae and Clostridiaceae members and 
decreasing Lactobacillaceae family members. The gut microbiota-transferred mice had a higher 
concentration of IgA and transforming growth factor-beta (TGF-β) in the lumen that was 
accompanied by an increase in CD8+CD103+ and CD8αβ T cells in the lamina propria of the 
large intestine. The data obtained in this study suggest that gut bacterial composition can be 
altered after the neonatal period, affects the mucosal immune system, and might delay the 
onset of autoimmune diabetes. These results have important implications for the develop-
ment of probiotic adjuvant treatment for T1D [24].
In 2015, Le and colleagues, from the National Institute for Food Control, by using C57BL/6 J 
mice with streptozotocin-induced diabetes, evaluated whether Bifidobacterium species induce 
the expression of proteins of the insulin signaling pathway and enhance adipocytokine gene 
expression. Oral administration of Bifidobacterium species significantly reduced blood glu-
cose levels and increased the protein expressions of insulin receptor beta, insulin receptor 
substrate 1, protein kinase B (Akt/PKB), IκB kinase alpha (IKKα), and nuclear factor-kappaB 
inhibitor alpha (IκBα). Bifidobacterium species also induce the adiponectin gene expression 
and decrease in macrophage chemoattractant protein-1 (MCP-1) and IL-6 expression. In con-
clusion, the results from this work suggest that Bifidobacterium species may be the promising 
bacteria for treat diabetes [25].
A study performed in Diabetes Research Institute, in Milan, Italy, by Dolpady and colleagues, 
in 2016, reported that the oral administration of a Lactobacillaceae-enriched probiotics VSL#3, 
alone or in combination with retinoic acid, protects NOD mice from diabetes by suppress-
ing inflammasome activation and IL-1β expression and by inducing the immunomodulatory 
indoleamine 2,3-dioxygenase (IDO) and IL-33 secretion. In addition, VSL#3-treated NOD 
mice showed modulation of the gut immunity by promoting differentiation of CD103+ tolero-
genic dendritic cells and suppressing the differentiation of inflammatory Th1 and Th17 sub-
sets in the gut mucosa [26].
Accumulating evidence supports that the intestinal microbiome is involved in T1D pathogenesis 
through the gut-pancreas axis. A recent study, performed in the University of British Columbia, 
in Canada, Brown and colleagues [27], aimed to determine whether the gut microbiota in the 
NOD mice played a role in T1D through the gut mucosa. To examine the effect of the intestinal 
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microbiota on T1D onset, scientists manipulated gut microbes by fecal transplantation between 
NOD and resistant NOD mice (NOR) and by oral antibiotic and probiotic treatment of NOD 
mice. The intestinal microbiota from NOD mice harbored more pathobionts and fewer benefi-
cial microbes in comparison with NOR mice. Fecal transplantation of NOD microbes induced 
insulitis in NOR hosts, suggesting that the NOD microbiome is diabetogenic. Moreover, anti-
biotic exposure accelerated diabetes onset in NOD mice accompanied by increased Th1 and 
Th17 cells in the mucosal-associated lymphoid tissues. The diabetogenic microbiome was char-
acterized by a metagenome altered in several metabolic gene clusters. Furthermore, diabetes 
susceptibility correlated with reduced fecal short chain fatty acids. In an attempt to correct the 
diabetogenic microbiome, researchers administered VLS#3 probiotic to NOD mice and found 
that VSL#3 colonized the intestine poorly and did not delay diabetes onset. Authors concluded 
that NOD mice harbor gut microbes that induce diabetes and that their diabetogenic microbi-
ome can be amplified early in life through antibiotic exposure. Protective microbes like VSL#3 
are insufficient to overcome the effects of a diabetogenic microbiome [27].
Another recent work, performed in Jiangnan University, in China, Jia and colleagues [28], 
investigated whether administration of probiotic Clostridium butyricum CGMCC0313.1 
(CB0313.1) could induce Treg cells in pancreas, and consequently inhibit the diabetes onset 
in NOD mice. CB0313.1 supplementation was delivered daily to female NOD mice from 3 to 
45 weeks of age. Researchers observed that probiotic administration suppressed the insuli-
tis, delayed the disease onset, and improved the glucose metabolism. These beneficial effects 
could involve the migration of intestinal Treg cells to the pancreatic lymph nodes and changes 
in the Th1/Th2/Th17 balance, favoring an anti-inflammatory milieu in the gut and pan-
creas. Additionally, probiotic supplementation increased the Firmicutes/Bacteroidetes ratio, 
Clostridium species, and butyrate-producing bacteria in the gut [28].
3.1.2. Probiotic applications in T1D patients
Probiotic supplementation has been hypothesized to affect innate and adaptive immune 
responses to environmental antigens by supporting healthy gut microbiota and could there-
fore be used to prevent the onset of T1D-associated islet autoimmunity and treat the stab-
lished disease [29].
In humans, a TEDDY study group, published in JAMA Pediatrics in 2016, evaluated the associ-
ation between probiotic supplementation and islet autoimmunity in children with genetic risk 
for T1D, during their first year of life. This multicenter prospective cohort study (United States, 
Finland, Germany, and Sweden) investigated 7473 children ranging from 4 to 10 years old. 
Early probiotic administration (0–27 days of life) was correlated with a decreased risk of islet 
autoimmunity when compared with the group that received probiotics after 27 days of life or 
no supplementation. This study concludes that early probiotic supplementation could decrease 
the risk of islet autoimmune reactions in children with high-genetic-risk alleles for T1D [30].
A current clinical trial, performed by Medical University of Warsaw, in Poland, involves the 
evaluation of the effect of Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 on β-cell 
function in children with newly diagnosed T1D. The double-blind, randomized, placebo-
controlled clinical trial included 96 children aged 8 to 17 years old. During 1 year, patients 
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received Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 at a dose of 109 colony-
forming units or an identically appearing placebo, orally, daily, for 6 months. The follow-up 
will be for 12 months. The primary outcome measures will be the area under the curve of the 
C-peptide levels during 2 h response to a mixed meal [31].
The Lactobacillus and Bifidobacterium are the major bacteria genera that make up the colon 
microbiota in humans and help in the intestinal microbial homeostasis, inhibit growth of 
pathobionts, improve the gut mucosal barrier, and modulate local and systemic immune 
responses. Intestinal dysbiosis may influence the immune system by increasing gut perme-
ability, intestinal inflammation, and impaired oral tolerance in T1D patients. Beneficial effect 
of Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 on β-cell function would create 
a rationale for its routine use in patients with newly diagnosed T1D [31]. Taken together, the 
studies imply that bacteriotherapy may potentially be used as a tool to modulate the immune 
system for preventing islet autoimmunity [31, 32].
3.2. Multiple sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory, autoimmune disease that affects the cen-
tral nervous system (CNS) and is characterized by immune reactions against myelin proteins 
and gangliosides. Susceptible HLA alleles and environmental factors, such as virus infection, 
a hypercaloric diet, vitamin D deficiency, and intestinal dysbiosis, have been implicated in 
triggering MS [33]. MS promotes disability in young adults and affects twice more women 
than men. According to the Multiple Sclerosis International Federation and World Health 
Organization, the prevalence of MS increased from 2.1 million in 2008 to 2.3 million in 2013 [34].
Studies have shown that gut microbiota can affect the development of MS, and these works 
implicated intestinal dysbiosis as one of the possible causes of extraintestinal disease devel-
opment [35]. The colonization of germ-free mice with segmented filamentous bacteria pro-
motes an increase in the number of Th17 cells in the lamina propria and CNS, worsening 
disease severity in experimental autoimmune encephalomyelitis (EAE), a MS animal model 
[36]. Likewise, the colonization of the same mice with Bacteroides fragilis and polysaccharide A 
(PSA), which induces Foxp3+ Treg cell differentiation, decreases symptoms in EAE mice [37].
3.2.1. Probiotics in experimental autoimmune encephalomyelitis
Several studies in experimental autoimmune encephalomyelitis (EAE) mice reported the 
immunomodulatory functions of probiotic administration. Treatment with Lactobacillus spe-
cies, Pediococcus acidolactici, Bifidobacterium bifidum, Bifidobacterium animalis, and Bacteroides fra-
gilis decreased CNS inflammation through the induction of Treg cells in the gastrointestinal 
mucosa, IL-10 and TGF-β secretion, and decreased expansion of Th1 and Th17 inflammatory 
subsets [37–40].
In previous studies, performed in National Institute for Public Health and the Environment, 
in the Netherlands, in 2008, Ezendam and colleagues evaluated the effect of the probiotic 
Bifidobacterium animalis on Th1- and Th2-mediated immune responses, including a rat EAE 
model. Bifidobacterium animalis administration started when the rats were 2 weeks old and 
EAE were induced when the animals were 6–7 weeks old. Bifidobacterium animalis significantly 
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reduced the duration of clinical symptoms by almost 2 days in males and improved the body 
weight gain during the experimental period compared with the control group [41]. In the 
same year, Maassen and colleagues presented data showing that strain-specific differences 
on the effect of commercially available probiotic depend on physiological use (normal route, 
dose, growth phase, specific strain, or substrain/species) and overwhelm (high dose) or cir-
cumvent natural immune processing [42].
Two years later, Lavasani and colleagues, from Lund University, in Sweden, evaluated the 
effect of five daily-administered Lactobacillus strains in inhibiting disease onset in EAE mice. 
The Lactobacillus paracasei DSM 13434 and Lactobacillus plantarum DSM 15312 and DSM 15313 
diminished autoreactive T cell responses and inflammation in the CNS. Lactobacillus paraca-
sei and Lactobacillus plantarum DSM 15312 induce Treg cells in mesenteric lymph nodes and 
TGF-β secretion. Lactobacillus plantarum DSM 15313 induces increase in the IL-27 serum con-
centrations. The isolated Lactobacillus strains failed to be therapeutic in EAE mice. On the 
other hand, the combination of three strains inhibited the disease progression and reversed 
the clinical and histological signs of EAE, probably by suppressing inflammatory Th1 and 
Th17 pathways and inducing regulatory mechanisms [43].
In 2010, Kobayashi and colleagues, from Yakult Central Institute for Microbiological Research, 
in Japan, evaluated the safety of two probiotic bacterial strains, Lactobacillus casei strain 
Shirota (LcS) and Bifidobacterium breve strain Yakult (BbY), that were orally administered to 
EAE Lewis rats. EAE was induced with a homogenate of guinea pig spinal cord as the sen-
sitizing antigen, and LcS was orally administered from 1 week before this sensitization until 
the end of the experiment. The oral administration of LcS tended to suppress the development 
of neurological symptoms. Differences in neurological symptoms between the control group 
and the administration groups did not reach statistical significance and support the notion 
that neither LcS nor BbY exacerbates EAE [44].
Two years later, Kobayashi and colleagues investigated the safety use of Lactobacillus casei 
strain Shirota (LcS) in prevention of EAE in a relapse and remission models. LcS was admin-
istered 1 week prior antigen sensitization until the end of the experiments. Probiotics did not 
exacerbate neurological symptoms or histopathological changes of the spinal cord in either 
model. LcS administration transiently induces IL-17 production by antigen-stimulated lym-
phocytes 7 days after sensitization. Increased production of IL-10 and an increase in the per-
centages of CD4+CD25+ Treg cells were observed. Strong expression of IL-17 mRNA was 
detected in the spinal cord of mice that displayed severe neurological symptoms on day 12, 
but this expression was not enhanced by LcS administration [45].
In 2013, Kwon and colleagues, from School of Life Sciences and Immune Synapse Research 
Center, in Republic of Korea, evaluated the prophylactic and therapeutic actions of a mix-
ture of five probiotics (IRT5) in EAE mice. IRT5 includes Lactobacillus casei, Lactobacillus 
acidophilus, Lactobacillus reuteri, Bifidobacterium bifidum, and Streptococcus thermophilus. IRT5 
prior treatment, before EAE induction, abrogated the disease development and delayed 
the EAE onset. Furthermore, the inflammatory subset Th1 and Th17 polarization was sup-
pressed by the administration of IRT5 probiotic. These actions were due probably by induc-
tion of CD4+Foxp3+ Treg cells and IL-10 secretion at sites of inflammation and peripheral 
lymph nodes [46].
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Three years later, Abdurasulova and coworkers, from Institute of Experimental Medicine, in St. 
Petersburg, Russian Federation, evaluated the effect of probiotic Enterococcus faecium strain L-3 
that was studied in EAE rats. Glatiramer acetate (GA) was used as control drug. Enterococcus 
faecium strain L-3 and GA were able to reduce the severity of EAE. Both approaches prolonged 
the inductive phase of EAE and reduced the disease duration. Study of the phenotypes of 
immune cells in the blood revealed the differences in immunoregulatory pathways that medi-
ate the protective action of probiotic or GA treatment of EAE. The presence of pronounced 
protective and immunomodulating effects of the probiotic Enterococcus faecium strain L-3 
opens an opportunity of its application for the adjuvant treatment of MS [47].
The Goudarzvand group [48], from School of Medicine, in Karaj, Iran, investigated the effect of 
Lactobacillus plantarum (LP) and Bifidobacterium B94 (BB94) on acquisition phase of spatial mem-
ory in the local demyelination of rats’ hippocampus. Thirty-two male Wistar rats were divided 
into control, damage group and treatment group. After the induction of demyelination, probi-
otics were administered by gavage for 28 days. Findings demonstrated that probiotics have no 
significant effect on swimming speed compared with lesion and saline groups. According to 
some studies, probiotics have a positive impact on improving the performance of spatial mem-
ory and learning, although this current study could not indicate finality of this assumption [48].
A recent study, performed by Secher and colleagues [49], from the University of Toulouse, 
in France, evaluated the effects of the probiotic Escherichia coli strain Nissle 1917 (ECN) in 
EAE model. The daily oral administration of ECN significantly decreased the disease severity 
induced by myelin oligodendrocyte glycoprotein (MOG) peptide mice immunization. The 
therapeutic effects could be explained by the increase in the IL-10 anti-inflammatory cytokine 
and reduction in inflammatory cytokines in the CNS and in the periphery. They also observed 
a decreased frequency of MOG-specific CD4+ T cells in the CNS, suggesting that ECN modu-
late the T cell homing from the lymph nodes to the CNS by affecting their activation and dif-
ferentiation. In this study, authors showed that EAE trigger is associated with increased gut 
permeability [49].
Another recent study, performed in Immunology Research Center, in Mashhad, Iran, Sale-
hipour and colleagues [50], evaluated the therapeutic effect of probiotic strains, Lactobacillus 
plantarum A7, Bifidobacterium animalis PTCC 1631, or both. Probiotics were administered orally 
for 22 days starting at same time with the induction of EAE in female C57BL/6 mice. Results 
showed that treatment with both strains caused a more significant delay in the time of disease 
onset and clinical score compared with strains used alone. Mononuclear cell infiltration into 
the CNS was significantly inhibited by the combinational approach. The treatment with both 
strains enhanced the population of CD4+CD25+Foxp3+ Treg cells in the lymph nodes and 
spleen. Additionally, Lactobacillus plantarum A7 and Bifidobacterium animalis ameliorated EAE 
condition by inhibiting IL-6 production, decreasing the release of IFN-γ, a Th1-type cytokine, 
and IL-17, a Th17 pro-inflammatory molecule, and increasing the secretion of IL-4, a Th2-type 
cytokine, and IL-10 and TGF-β, anti-inflammatory cytokines, in the lymph nodes and spleen. 
The treatment with Bifidobacterium animalis induced a downregulation of transcription factors 
T-bet and ROR-γt that generate Th1 and Th17 inflammatory subsets, in the brain and spleen, 
and promoted an upregulation of GATA3 and Foxp3, which contributes for the Th2 and Treg 
cell differentiation [50].
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3.2.2. Probiotic applications in MS patients
Probiotic applications based on the hygiene hypothesis, such as administration of the eggs from 
nonpathogenic helminth Trichuris suis ova (TSO), have proven safe and effective in autoimmune 
inflammatory bowel disease. Based on this, Fleming and colleagues [6], from the University 
of Wisconsin, in the United States, evaluated the safety and effects of TSO administration in 
newly diagnosed, non-treated relapsing-remitting MS patients. Researchers conducted the 
phase 1 helminth-induced immunomodulatory therapy (HINT 1) study by enrollment of five 
MS patients that took orally 2500 TSO, every 2 weeks, for 3 months. The preliminary outcomes 
showed increase in the serum levels of IL-4 and IL-10 cytokines and decreased in the mean 
number of new gadolinium-enhancing magnetic resonance imaging (MRI) lesions. TSO was 
well tolerated in this first human study of the probiotic application in relapsing-remitting MS, 
and favorable trends were observed in exploratory MRI and immunological parameters [6].
Two years later, Rosche and colleagues, from the Department of Neurology and Experimental 
Neurology, in Berlin, Germany, evaluated the administration of 2500 Trichuris suis ova eggs orally, 
every 2 weeks, for 12 months, in relapsing-remitting MS patients. Fifty patients with relapsing-
remitting MS with clinical activity, not undergoing any standard therapies, were enrolled. The 
safety, tolerability, and effect on disease activity and in vivo mechanisms of action of TSO in MS 
will be assessed by neurological, laboratory, and immunological exams and MRI throughout the 
12-month treatment period and over a follow-up period of 6 months. No adverse effects were 
observed, and the Trichuris suis ova group was more effective than the placebo in preventing new 
T2 and gadolinium-positive lesions, quantified by MRI. Authors also expect the Th1 and Th17 
pro-inflammatory responses polarize toward the anti-inflammatory Th2 response [51].
In a recent study, Kouchaki and colleagues [52], from School of Medicine from Kashan, in 
Islamic Republic of Iran, reported improved Expanded Disability Status Score (EDSS), insulin 
resistance, and a decrease in inflammatory markers in MS patients treated with probiotic sup-
plementation containing Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus fermentum, 
and Bifidobacterium bifidum. This randomized double-blind, placebo-controlled clinical trial 
analyzed probiotic intake for 12 weeks in 60 MS patients. Compared with the placebo group, 
probiotic administration improved EDSS, beck depression inventory, general health ques-
tionnaire, and depression anxiety and stress scale. Furthermore, changes in high-sensitivity 
C-reactive protein, plasma nitric oxide metabolites, and malondialdehyde in the probiotic 
group were significantly different from the changes in these parameters in the control group. 
In addition, the probiotic intake significantly decreased insulin levels and total high-density 
lipoprotein (HDL) cholesterol and significantly increased quantitative insulin sensitivity 
check index and HDL-cholesterol levels compared with the placebo [52].
Another recent randomized, double-blind, placebo-controlled clinical trial, performed in 
Islamic Republic of Iran, by Tamtaji and colleagues [53], evaluated the role of probiotic admin-
istration on gene expression associated to inflammatory, glucose, and lipid signaling pathways 
in MS patients. The study included 40 patients with MS. Participants were randomly assigned 
into two groups to receive either a probiotic capsule containing Lactobacillus acidophilus, 
Lactobacillus casei, Bifidobacterium bifidum, and Lactobacillus fermentum (2 × 109 colony-forming 
units/g each) or placebo, for 12 weeks. Researchers observed that probiotic administration 
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downregulated gene expression of IL-8 and TNF-α mRNA in peripheral blood mononuclear 
cells of MS patients. On the other hand, probiotics did not affect the gene expression of IL-1, 
peroxisome proliferator-activated receptor gamma (PPAR-γ), or oxidized low-density lipo-
protein receptor (LDLR) in peripheral blood mononuclear cells of MS patients [53].
3.3. Rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterized by chronic 
inflammation of multiple joints, bone erosion, and cartilage destruction. Moreover, RA can 
affect internal organs such as the lungs, heart, and kidneys. Anti-cyclic citrullinated peptide 
and rheumatoid factor are the most important autoantibodies in RA and can be found before 
disease onset [54]. The disease is three times more common in women, and according to the 
World Health Organization, the worldwide prevalence, which is between 0.3 and 1%, ranks 
the disease among the most common autoimmune disorders. The triggering of RA involves 
the interaction of HLA genes and environmental factors, such as smoking and infections [55]. 
Among environmental factors, dysbiosis has been identified as a possible trigger factor for 
autoimmunity and RA development [56].
3.3.1. Probiotics in animal models of RA
Experiments in animal models suggest that gut microbiota influences local and systemic 
immunity and might trigger joint inflammation [57]. Studies in collagen-induced arthritic 
(CIA) mice showed that the administration of antibiotics exacerbates the disease and increases 
the level of IL-6, IFN-γ, and IL-17 pro-inflammatory cytokines. Further study showed differ-
ences in the gut microbiota composition between CIA-susceptible and CIA-resistant mice, 
with a prevalence of Desulfovibrio, Prevotella, Parabacteroides, Odoribacter, Acetatifactor, Blautia, 
Coprococcus, and Ruminococcus genera in arthritic mice, in addition to increased levels of 
serum IL-17 and CD4 Th17 cells in the spleen [58].
The study performed by Abhari and colleagues [59], in Shiraz University, in Iran, investigated 
the possible role of probiotic Bacillus coagulans and prebiotic inulin on the downregulation of 
immune responses and the progression of RA, by using rat models of the disease. The spore-
forming probiotic strain Bacillus coagulans has an anti-inflammatory and immunomodulatory 
effects in animals and humans. The treatment with the probiotic and prebiotic significantly 
inhibits serum amyloid A in arthritic rats, and a significant decrease in the secretion of the 
pro-inflammatory TNF-α was detected [59].
Another work, performed in the Department of Probiotics Immunology, Sapporo University, in 
Japan, Yamashita and colleagues [60], evaluated the effect of the oral administration of Lactobacillus 
helveticus SBT2171 on CIA development and on the regulation of antigen-specific antibody pro-
duction and inflammatory immune cells, implicated in the RA development. Probiotic admin-
istration promotes decrease in joint swelling, body weight loss, and the serum level of bovine 
type II collagen (CII)-specific antibodies in the CIA mouse model. In addition, the intraperitoneal 
inoculation of Lactobacillus helveticus SBT2171 also decreased the arthritis incidence, joint dam-
age, and serum concentrations of IL-6. Furthermore, the numbers of total immune cells, total 
B cells, germinal center B cells, and CD4+ T cells in the draining lymph nodes were decreased 
following intraperitoneal inoculation of Lactobacillus helveticus SBT2171. Findings of this study 
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demonstrated the ability of Lactobacillus helveticus SBT2171 to downregulate the abundance of 
immune cells and the subsequent production of CII-specific antibodies and IL-6, thereby sup-
pressing the CIA symptoms, indicating its potential for use in the prevention of RA [60].
Lactobacillus helveticus SBT2171 (LH2171) is a lactic acid bacterium with high protease activity 
and used in starter cultures in the manufacture of cheese. Scientists have demonstrated that 
LH2171 inhibited the proliferation of lipopolysaccharide (LPS)-stimulated mouse T and B 
cells and the human lymphoma cell lines, Jurkat and BJAB. The findings of this study suggest 
that LH2171 inhibits the proliferation of lymphocytes through the suppression of the JNK 
signaling pathway and exerts an immunosuppressive effect in vivo, reinforcing their use in 
treatment of immune-mediated diseases [61].
Intestinal dysbiosis has been previously identified in patients with RA, and the administration 
of certain probiotics showed an improvement in RA. Study from Gohil and colleagues [62], 
from the Institute of Pharmaceutical Education and Research, in Gujarat, India, was designed 
to find out the antiarthritic activity of cell wall content of Lactobacillus plantarum in complete 
Freund’s adjuvant (CFA)-induced arthritis in rats. The change in body weight, paw volume 
and arthritic index, joint stiffness, gait test, mobility test, erythrocyte sedimentation rate, 
serum C-reactive protein level, serum rheumatoid factor, and serum TNF-α was measured on 
day 21. Cell wall content of Lactobacillus plantarum-treated animals showed improvement in all 
the parameters as compared to that in CFA-treated animals and exert antiarthritic activity [62].
3.3.2. Probiotic applications in RA patients
Some performed studies evaluating the effect of probiotics as an adjuvant therapy for RA 
treatment have shown no significant results, and some of these conducted studies have 
smaller number of patients and a short period of evaluation [63, 64].
The earliest study to evaluate the efficacy of probiotics in RA was performed in Rheumatism 
Foundation Hospital, in Finland, and was published in 2003. In a pilot study, Hatakka and col-
leagues evaluated 25 non-treated RA patients that were randomized to receive either two capsules 
of a Lactobacillus rhamnosus or placebo, twice daily for a year. Overall, no statistically significant 
differences were seen between the case and the placebo. Both groups had a decline in tender and 
swollen joints, and the physician global scores improved in the probiotic group. Mean eryth-
rocyte sedimentation rates and C-reactive protein levels remained normal in both groups. The 
serum concentrations of IL-1β increase in patients treated with Lactobacillus species; however, this 
increase was not associated with any detectable change in disease status. Fecal sampling showed 
an increase in the presence of Lactobacillus rhamnosus in the probiotic group at 1 year. Based on 
these results, researchers concluded that Lactobacillus rhamnosus preparation did not alter RA 
activity. However, study cohort was small, and enrolled patients have low disease activity [65].
A double-blind, placebo-controlled clinical trial, performed in the University of Western 
Ontario, Canada, by Pineda and colleagues [63], evaluated the effect of the oral administra-
tion of Lactobacillus rhamnosus and Lactobacillus reuteri for 3 months to 29 RA patients. Fifteen 
patients were randomized to the probiotic group and 14 to placebo. Alterations in cytokines 
favored placebo over probiotic group. There was a significant improvement in the Health 
Assessment Questionnaire score in the probiotic group. Although researchers did not detect 
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clinical improvement, measured by the American College of Rheumatology criteria, authors 
reported functional improvement within the probiotic supplementation group compared 
with the placebo [63].
Another randomized, double-blind placebo-controlled trial, performed in Tabriz University 
of Medical Sciences, in Iran, by Vaghef-Mehrabany and colleagues [64], investigated the 
role of Lactobacillus casei 01 intake in 46 RA patients for 8 weeks. This clinical trial showed 
improvement in disease activity score, increased levels of serum IL-10, and decreased levels 
of pro-inflammatory TNF-α, IL-6, and IL-12 cytokines in treated patients. In this study, scien-
tists concluded that supplementation improved the disease activity and inflammatory status 
in RA patients [64].
Another clinical trial, with the same study design, performed by Zamani and colleagues [66], 
in Kashan University of Medical Sciences, Iran, evaluated the effect of probiotic administra-
tion on clinical and metabolic parameters in RA patients. Sixty patients aged 25–70 years were 
enrolled into two groups to receive either probiotic or placebo. Probiotic group received a daily 
capsule containing three strains: Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium 
bifidum, for 8 weeks. After intervention, probiotic administration improved Disease Activity 
Score of 28 joints (DAS-28). In addition, a significant decrease in serum insulin levels, homeo-
static model assessment-B cell function (HOMA-B), and serum high-sensitivity C-reactive 
protein concentration was also observed in the probiotic group [66].
3.4. Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune and heterogeneous disease character-
ized by damage to the skin, kidneys, lungs, joints, heart, and brain [67]. The disease affects 
mainly females, and its worldwide prevalence varies from 30 to 60 per 100,000 in the United 
Kingdom and the United States [68]. SLE pathogenesis may involve genetic and environmen-
tal factors, such as viral infections, defective apoptosis, elevated oxidative stress, and solar 
exposure to ultraviolet-B waves. Regarding immune response, it is known that autoantibodies 
bind mainly with nuclear and cytoplasmic antigens [69]. Moreover, increased evidence has 
emerged in a recent year that suggests the role of intestinal dysbiosis in SLE development [70].
3.4.1. Probiotics in animal models of SLE
In female lupus-prone mice, Zhang and colleagues [71] reported a decrease in the relative abun-
dance of Lactobacillus species and an increase in Lachnospiraceae members when compared with 
controls. Early disease onset and severe symptoms correlated with increased Lachnospiraceae 
reads in female lupus-prone mice. Additionally, the number of Clostridiaceae and Lachnospiraceae 
reads increased at specific time points during disease progression [71]. Another study reported 
that dietary intervention, such as caloric restriction, in NZB/WF1 mice promoted changes in the 
intestinal microbiota and delayed disease progression in this animal model [72].
In a lupus-like animal model, the administration of retinoic acid restored Lactobacillus species 
and improved lupus symptoms, suggesting the use of these species as a probiotic to diminish 
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inflammation in SLE patients [71]. Some Lactobacillus species have been demonstrated to have 
immunomodulatory properties in the host gut mucosa, such as inhibiting neutrophil extracel-
lular trap formation, improving antioxidant status, and increasing the expression of adhesion 
molecules in the gut [73, 74].
In a recent study, performed by Tzang and colleagues [75], in Chung Shan Medical University, 
in Taiwan, scientists investigated the effects of oral administration of Lactobacillus paraca-
sei GMNL-32, Lactobacillus reuteri GMNL-89, and Lactobacillus reuteri GMNL-263 in NZB/W 
F1 mice. When researchers evaluated the administration of the three probiotic strains, they 
observed a significant decrease in IL-6 and TNF-α serum concentrations and increase in antiox-
idant activity in serum and liver samples (higher glutathione GSH and 1,1-diphenyl-2-picryl-
hydrazyl levels and lower malondialdehyde levels). Additionally, the supplementation with 
Lactobacillus reuteri GMNL-263 significantly increased the differentiation of CD4+CD25+FoxP3+ 
Treg cells in NZB/W F1 mice, suggesting that these strains could be used as adjuvant treatment 
of SLE patients [75]. Another investigation from the same group demonstrated that supple-
mentation with these three probiotic strains ameliorates hepatic apoptosis, matrix metallo-
proteinase-9 activity, C-reactive protein, and inducible nitric oxide synthase expressions. In 
addition, probiotics decrease the gene expression of hepatic IL-1β, IL-6 and TNF-α proteins, by 
suppressing the mitogen-activated protein kinase and NF-κB signaling pathways [76].
Although some studies in SLE animal models showed promising results using probiotic sup-
plementation, currently, there are no clinical trials reported at clinicaltrials.gov investigating 
the role of probiotics as an adjuvant therapy in the treatment of SLE patients.
4. Conclusions
Evidences associate intestinal dysbiosis with autoimmune disease pathogenesis. Impaired 
gut microbiota function and diversity could represent a trigger site of autoimmunity by neo-
antigen generation under dysbiotic conditions. Emerging findings point to the use of pro-
biotics as a preventive functional food and as adjuvant treatment of autoimmune diseases. 
However, further clinical trials, with large cohorts, to evaluate the security and efficacy of the 
probiotic administration in patients with autoimmune diseases are needed.
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Appendices and nomenclature
Treg T regulatory cells
T1D Type 1 diabetes
NOD mice Nonobese diabetic mice
IL Interleukin
TNF-α Tumor necrosis factor-alpha
TGF-β Transforming growth factor-beta
MCP-1 Macrophage chemoattractant protein-1
IDO Indoleamine 2,3-dioxygenase
NOR mice Resistant NOD mice
TEDDY The Environmental Determinants of Diabetes in the Young
MS Multiple sclerosis
CNS Central nervous system
EAE Experimental autoimmune encephalomyelitis
PSA Polysaccharide A
GA Glatiramer acetate
MOG Myelin oligodendrocyte glycoprotein
TSO Trichuris suis ova
MRI Magnetic resonance imaging
EDSS Expanded Disability Status Score
HDL High-density lipoproteins
RA Rheumatoid arthritis
CIA mice Collagen-induced arthritic mice
LPS Lipopolysaccharide
CII Type II collagen-specific antibodies
NZB New Zealand black mice
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